Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Versus Without Chronic Kidney Disease.
Aged
Aged, 80 and over
Coronary Artery Bypass
Coronary Artery Disease
/ epidemiology
Female
Glomerular Filtration Rate
Humans
Japan
/ epidemiology
Kidney Failure, Chronic
/ epidemiology
Male
Middle Aged
Percutaneous Coronary Intervention
Proportional Hazards Models
Registries
Renal Dialysis
Renal Insufficiency, Chronic
/ epidemiology
Severity of Illness Index
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
05
11
2020
revised:
28
12
2020
accepted:
31
12
2020
pubmed:
18
1
2021
medline:
17
4
2021
entrez:
17
1
2021
Statut:
ppublish
Résumé
Chronic kidney disease (CKD) might be an important determinant in choosing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). However, there is a scarcity of studies evaluating the effect of CKD on long-term outcomes after PCI relative to CABG in the population including severe CKD. Among 30257 consecutive patients patients who underwent first coronary revascularization with PCI or isolated CABG in the CREDO-Kyoto PCI/CABG registry Cohort-2 (n = 15330) and Cohort-3 (n = 14,927), we identified the current study population of 12,878 patients with multivessel or left main disease, and compared long-term clinical outcomes between PCI and CABG stratified by the subgroups based on the stages of CKD (no CKD: eGFR >=60 ml/min/1.73m
Identifiants
pubmed: 33454346
pii: S0002-9149(21)00036-9
doi: 10.1016/j.amjcard.2020.12.079
pii:
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-46Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures Dr. Morimoto reports honoraria from Bayer and Kowa, and expert witness from Boston Scientific and Sanofi. Dr. Shiomi reports honoraria from Abbott Vascular, and Boston Scientific. Dr. Furukawa reports honoraria from Bayer, Kowa, and Sanofi. Dr. Nakagawa reports research grant from Abbott Vascular and Boston Scientific, and honoraria from Abbott Vascular, Bayer, and Boston Scientific. Dr. Kimura reports honoraria from Abbott Vascular, Astellas, AstraZeneca, Bayer, Boston Scientific, Kowa, and Sanofi.